18.2 Thunderclap & Acute Severe Secondary Headaches

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

18.2 Thunderclap & Acute Severe Secondary Headaches

Key Takeaways Explain This Topic AI

A thunderclap headache is defined as a hyperacute, excruciating headache reaching peak maximal intensity within 60 seconds of onset ('worst headache of life'); ruptured aneurysmal subarachnoid hemorrhage (SAH) accounts for ~85% of non-traumatic cases, predominantly originating from the anterior or posterior communicating arteries.

The Ottawa SAH Rule provides 100% sensitivity for alert adult patients with peak headache within 1 hour; a non-contrast head CT performed within 6 hours of headache onset using a modern multi-detector scanner achieves >99% sensitivity, safely excluding SAH if negative and interpreted by an experienced radiologist.

If a non-contrast head CT is performed >6 hours after headache onset or yields equivocal results, a mandatory lumbar puncture must be performed to evaluate opening pressure, failure of CSF RBC clearance across tubes 1 to 4, and xanthochromia (yellow CSF supernatant from hemoglobin degradation into bilirubin, requiring 6–12 hours to develop in vivo).

Emergency medical stabilization of aneurysmal SAH mandates strict blood pressure control (target systolic blood pressure <140 mm Hg using IV nicardipine or labetalol) to prevent catastrophic early rebleeding, alongside oral nimodipine 60 mg every 4 hours for 21 days to prevent delayed cerebral ischemia (strictly avoiding intravenous nimodipine due to fatal cardiovascular collapse).

The differential diagnosis of thunderclap headache encompasses Reversible Cerebral Vasoconstriction Syndrome (RCVS, postpartum/vasoactive triggers), Cerebral Venous Sinus Thrombosis (hypercoagulable state, papilledema), Cervical Artery Dissection (unilateral neck pain, partial Horner syndrome, ischemic stroke), and Pituitary Apoplexy (bitemporal hemianopsia, cranial nerve palsies, acute secondary adrenal crisis requiring emergent IV hydrocortisone).

Last updated: September 2026

Thunderclap Headache: Clinical Definition & Urgent Differential Diagnosis

A Thunderclap Headache (TCH) is clinically defined as an excruciating, explosive headache that peaks at maximal intensity within 60 seconds of onset. Patients frequently characterize the event as "the worst headache of my entire life" or describe feeling as though they were "struck in the back of the head with a baseball bat." TCH is a true medical emergency: approximately 20% to 25% of patients presenting with a true thunderclap headache harbor a life-threatening secondary underlying vascular etiology.

Comprehensive Differential Diagnosis of Thunderclap Headache

Etiology Pathophysiological Mechanism Distinguishing Clinical Features & Exam Red Flags First-Line Diagnostic Modality

Aneurysmal Subarachnoid Hemorrhage (SAH) ; (~85% of non-traumatic SAH) Rupture of an intracranial saccular (berry) aneurysm into the subarachnoid space; most common sites: Anterior Communicating Artery (ACom, ~35%), Posterior Communicating Artery (PCom, ~25%), Middle Cerebral Artery (MCA, ~20%) Meningismus (nuchal rigidity, photophobia, positive Kernig/Brudzinski signs; delayed 6–12 hours), preretinal subhyaloid hemorrhages ( Terson syndrome ), CN III palsy with pupil dilation (PCom aneurysm compression), syncope Non-contrast Head CT within 6 hours; if negative or >6 hours, Lumbar Puncture for RBCs and xanthochromia

Reversible Cerebral Vasoconstriction Syndrome (RCVS) Transient, reversible multifocal segmental vasoconstriction and dilation of medium-to-large cerebral arteries Recurrent thunderclap headaches occurring over days to weeks; triggered by the postpartum state, sexual activity, Valsalva, or vasoactive exposures (SSRIs, SNRIs, nasal decongestants, triptans, cocaine, cannabis); often benign CSF Non-contrast Head CT (often normal), followed by CTA/MRA showing diffuse segmental "string-of-beads" vasoconstriction resolving within 3 months

Cerebral Venous Sinus Thrombosis (CVST) Occlusive thrombosis within dural venous sinuses (superior sagittal, transverse, or sigmoid sinus) causing venous congestion and intracranial hypertension Female predominance, hypercoagulable states (pregnancy, oral contraceptives, factor V Leiden, malignancy); progressive headache, papilledema , seizures, focal neurological deficits, and petechial lobar venous infarcts Magnetic Resonance Venography (MRV) or CT Venography (CTV); "empty delta sign" on contrast CT

Cervical Artery Dissection (Carotid or Vertebral) Intimal tear allowing blood to dissect into the vessel media, creating an intramural hematoma, luminal stenosis, or thromboembolism Internal Carotid Dissection : Unilateral frontotemporal headache, ipsilateral neck/facial pain, partial Horner syndrome (ptosis and miosis WITHOUT anhidrosis, as sweat fibers travel with the external carotid), TIA/MCA stroke.; Vertebral Dissection : Unilateral occipitonuchal pain, Wallenberg syndrome (lateral medullary stroke), cerebellar ataxia Contrast CT Angiography (CTA) or Magnetic Resonance Angiography (MRA) of the neck and head (mural hematoma, crescent sign)

Pituitary Apoplexy Hyperacute infarction or hemorrhage into a pre-existing pituitary macroadenoma Severe retro-orbital or bifrontal headache, bitemporal hemianopsia (optic chiasm compression), ophthalmoplegia / diplopia (compression of CN III, IV, VI in cavernous sinus), and acute secondary adrenal crisis (hypotension, hyponatremia, hypoglycemia) MRI Brain (pituitary protocol); immediate IV stress-dose hydrocortisone (100 mg IV) prior to imaging

Acute Angle-Closure Glaucoma Pupillary block mechanically closing trabecular meshwork; sudden spike in intraocular pressure (IOP >40–70 mm Hg) Unilateral ocular pain radiating to frontal head, nausea, vomiting, colored halos around lights, cloudy/steamy cornea, fixed mid-dilated pupil Tonometry (elevated IOP); urgent ophthalmology consultation

Diagnostic Evaluation of Suspected SAH: The Ottawa Rule, 6-Hour CT & LP
The Ottawa Subarachnoid Hemorrhage Rule

The Ottawa SAH Rule was prospectively validated in alert, neurologically intact adult patients (age ≥15 years) presenting with a new acute, non-traumatic headache peaking within 1 hour. It demonstrates 100% sensitivity (and ~15% specificity) for identifying subarachnoid hemorrhage. Diagnostic workup (non-contrast head CT) is mandated if ANY ONE of the following 6 criteria is met:

Age ≥40 years
Complaint of neck pain or neck stiffness
Witnessed loss of consciousness
Onset during exertion (e.g., heavy lifting, sports, sexual intercourse, Valsalva)
Thunderclap headache (pain peaking instantly / <1 minute)
Limited neck flexion on physical examination (inability to touch chin to chest)

Rule Caveat : The Ottawa rule applies only to alert patients with GCS 15. Patients with altered sensorium, focal neurologic deficits, or known prior intracranial aneurysms bypass clinical rules and proceed directly to emergency neuroimaging.

The 6-Hour Non-Contrast Head CT Rule

The timing of non-contrast head CT is the single most critical factor determining its sensitivity for subarachnoid blood:

Within 6 Hours of Headache Onset : In landmark prospective multicenter trials (Perry et al.), a modern multi-detector (≥16-slice) non-contrast head CT performed within 6 hours of headache onset and interpreted by an experienced radiologist has a sensitivity >99.9% and a negative predictive value >99.9%.

Guideline Mandate : If an alert, neurologically intact patient presents within 6 hours of onset and a high-quality non-contrast head CT is completely normal, aneurysmal SAH is safely ruled out. In this specific scenario, routine follow-up lumbar puncture can be safely omitted.

Beyond 6 Hours from Onset: The Mandatory Lumbar Puncture (LP)

As time elapses beyond 6 hours, CSF bulk flow clears extravasated erythrocytes, and macrophage phagocytosis lyses red blood cells, causing CT sensitivity to decline precipitously:

24 Hours : Sensitivity falls to ~85%–90%.

48 Hours : Sensitivity falls to ~75%.

1 Week : Sensitivity falls to ~50%.

Clinical Mandate : If a patient presents more than 6 hours after headache onset , or if the non-contrast head CT is technically inadequate, equivocal, or negative in the face of high clinical suspicion, a Lumbar Puncture (LP) is strictly mandatory . SUSPECTED SAH DIAGNOSTIC CASCADE

┌────────────────────────────────────────────────────────┐
│ Acute Non-Traumatic Headache (Peaking within 1 Hour) │
└───────────────────────────┬────────────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Apply Ottawa SAH Rule (Age ≥40, Neck stiffness/pain, │
│ Exertion, LOC, Thunderclap, Restricted neck flexion) │
└───────────────────────────┬────────────────────────────┘
│
┌───────────────┴───────────────┐
│ ALL 6 Criteria Negative? │
├───────────────┬───────────────┤
│ YES │ NO (≥1 Met) │
▼ ▼ │
┌─────────────────────┐ ┌─────────────────────────────────────┐
│ SAH Safely Excluded │ │ Urgent Non-Contrast Head CT │
│ No CT or LP required│ └──────────────────┬──────────────────┘
└─────────────────────┘ │
┌───────────────┴───────────────┐
│ CT Scan Timing from Onset │
├───────────────┬───────────────┤
│ ≤6 Hours │ >6 Hours │
▼ ▼ │
┌───────────────────────────────┐ ┌───────────────────────────────┐
│ CT Negative: SAH Ruled Out │ │ CT Negative: Sensitivity Low │
│ (Sens >99%; No LP needed │ │ LP IS MANDATORY │
│ if intact, 3rd-gen CT) │ │ Check Opening Pressure, │
└───────────────────────────────┘ │ Tube 1-4 RBCs, Xanthochromia │
└───────────────┬───────────────┘
│
┌─────────────────────────┴───────────────┐
│ Xanthochromia (+) OR Persistent RBCs │
├─────────────────────────┬───────────────┤
│ Positive │ Negative │
▼ ▼ │
┌─────────────────────────┐ ┌─────────────────────┐
│ CONFIRMED SAH │ │ SAH Ruled Out │
│ • Emergent CTA Brain │ │ Search other causes │
│ • Target SBP <140 mmHg │ └─────────────────────┘
│ • Oral Nimodipine │
│ • Emergent Neurosurgery │
└─────────────────────────┘
Lumbar Puncture CSF Analysis: SAH vs Traumatic Tap

Performing an LP in suspected SAH requires systematic evaluation of three critical parameters:

Opening Pressure : Measured in the lateral decubitus position. Normal is 10 to 20 cm H2O. Elevated in SAH (>20 cm H2O) due to obstruction of arachnoid granulations by extravasated red blood cells.

Serial RBC Count (Tubes 1 to 4) :

Aneurysmal SAH : Red blood cell counts remain persistently and uniformly elevated across all tubes (tube 1 to tube 4), with <25% clearance.

Traumatic Tap : Puncture of an epidural or subarachnoid venule by the spinal needle causes high RBCs in tube 1 that dramatically clear or decline by >50% to 75% by tube 4.

Xanthochromia (The Gold Standard for Prior Bleeding) :

Biochemical Mechanism : When erythrocytes enter the CSF in vivo, they are engulfed by arachnoid reticuloendothelial macrophages. Hemoglobin is enzymatically cleaved into oxyhemoglobin (pink/orange) and subsequently into bilirubin (yellow). The yellow pigmentation of the centrifuged CSF supernatant is termed xanthochromia .

Timeline : Xanthochromia requires 6 to 12 hours to develop in vivo after an initial subarachnoid hemorrhage, reaches maximal intensity at 48 hours, and persists for 2 to 4 weeks.

Detection : Visual inspection against a white background or, preferably, spectrophotometry (which detects light absorbance peaks at 415 nm for oxyhemoglobin and 450–460 nm for bilirubin).

Key Exam Distinction : In a traumatic tap, intact erythrocytes have not undergone in-vivo enzymatic conversion into bilirubin. When a traumatic tap sample is immediately centrifuged, the supernatant is crystal clear and completely negative for xanthochromia.

Emergency Resuscitation & Critical Care Management of SAH

Once aneurysmal SAH is identified, management focuses on preventing catastrophic early complications: rebleeding and delayed cerebral ischemia (DCI) .

1. Airway, Breathing & Intensive Monitoring

Endotracheal intubation with rapid sequence induction for patients with GCS ≤8, loss of airway protective reflexes, or acute intracranial hypertension.

Immediate transfer to a dedicated Neurointensive Care Unit (NICU).

2. Acute Blood Pressure Control

The Danger of Rebleeding : The incidence of aneurysmal rebleeding is highest in the first 2 to 24 hours (peak 4–10%), carrying a catastrophic case-fatality rate of 50% to 70%.

Blood Pressure Target : Maintain Systolic Blood Pressure (SBP) <140 mm Hg (or Mean Arterial Pressure [MAP] <110 mm Hg) while maintaining adequate cerebral perfusion pressure (CPP ≥60 mm Hg).

First-Line Antihypertensives :

IV Nicardipine Infusion : Titratable dihydropyridine calcium channel blocker. Start at 5 mg/h IV; titrate by 2.5 mg/h every 5 to 15 minutes up to a maximum of 15 mg/h.

IV Clevidipine : Ultra-short-acting lipid emulsion calcium channel blocker (1–2 mg/h, double every 90 seconds).

IV Labetalol : Combined alpha/beta-blocker (10–20 mg IV bolus over 2 minutes, repeatable or infused at 2–8 mg/min).

Agent to Avoid : Sodium nitroprusside is strictly avoided because it dilates cerebral venules, increasing intracranial blood volume and dangerously elevating ICP.

3. Prevention of Delayed Cerebral Ischemia (DCI) / Vasospasm

Cerebral vasospasm is the delayed arterial narrowing occurring 4 to 14 days post-SAH (peaking at days 7 to 10), driven by spasmogenic spasmolytic imbalance from hemoglobin breakdown products (oxyhemoglobin, endothelin-1).

Oral Nimodipine (Guideline Mandate) :

Dosing : 60 mg orally (or via nasogastric tube) every 4 hours for 21 consecutive days .

Mechanism : Lipophilic dihydropyridine calcium channel blocker that readily crosses the blood-brain barrier. It does not prevent macrovascular arterial narrowing on angiograms; rather, it provides cellular neuroprotection, prevents microvascular microthrombosis, and improves functional neurological survival.

BLACK BOX WARNING : Nimodipine capsules must NEVER BE ADMINISTERED INTRAVENOUSLY . If drawn up into a syringe to administer via a feeding tube, accidental IV injection causes profound refractory peripheral vasodilation, irreversible cardiogenic shock, and death. Syringes must be clearly labeled "NOT FOR IV USE."

Maintenance of Euvolemia :

Historical "Triple-H therapy" (hypervolemia, hemodilution, hypertension) is obsolete. Clinical trials proved that aggressive hypervolemia increases pulmonary edema, myocardial infarction, and death without improving cerebral ischemia.

Modern standard: Maintain strict euvolemia with isotonic crystalloid (0.9% normal saline at 1–1.5 mL/kg/h). Avoid hypotonic fluids (D5W, 0.45% saline) which exacerbate cerebral edema.

Induced Hypertension : If delayed cerebral ischemia (new focal deficit or GCS decline) develops after the aneurysm has been secured, induce hypertension with IV vasopressors (norepinephrine or phenylephrine) to drive collateral cerebral blood flow.

4. Acute Hydrocephalus & Seizure Prophylaxis

Acute Obstructive Hydrocephalus : Occurs in 20% to 30% of SAH patients due to blood clogging the arachnoid granulations or ventricular foramen of Monro. Requires emergent bedside External Ventricular Drain (EVD / ventriculostomy) placement by neurosurgery.

Seizure Prophylaxis : A transient seizure raises ICP and precipitates aneurysm rebleeding. Short-term antiepileptic prophylaxis (e.g., Levetiracetam [Keppra] 500–1000 mg IV twice daily ) is recommended during the acute peri-rupture period (discontinued after aneurysm securing unless active seizures occur).

5. Definitive Aneurysm Securing

Emergent neurointerventional or neurosurgical evaluation within 24 hours to definitively secure the ruptured aneurysm and prevent rerupture.

Endovascular Coiling : Platinum coils are threaded via femoral/radial catheter into the aneurysm dome, promoting thrombosis. Demonstrated lower 1-year disability and mortality compared to surgery in the International Subarachnoid Aneurysm Trial (ISAT), especially for posterior circulation and anterior communicating aneurysms.

Surgical Clipping : Open craniotomy with microsurgical placement of a spring-loaded metallic clip across the aneurysm neck. Preferred for middle cerebral artery (MCA) bifurcations, wide-necked aneurysms, or large concurrent parenchymal hematomas requiring mass-effect evacuation.

High-Yield Secondary Headache Mimics: Clinical Pearls
Reversible Cerebral Vasoconstriction Syndrome (RCVS)

Characterized by multiple, recurrent thunderclap headaches occurring over 1 to 4 weeks ("headache storms").

Triggered by sympathetic activation (crying, sexual intercourse, straining) or exposure to vasoactive chemicals: SSRIs, SNRIs, sumatriptan, pseudoephedrine, cocaine, ecstasy, amphetamines, and cannabis.

Cerebral angiography reveals diffuse, multifocal "string-of-beads" arterial narrowing that spontaneously resolves within 12 weeks.

Treatment: Discontinue offending vasoactive drugs; administer oral calcium channel blockers (e.g., verapamil or nimodipine) to relieve arterial spasm.

Pituitary Apoplexy

Acute infarction or hemorrhage into an unsuspected or known pituitary macroadenoma.

Cardinal presentation: Sudden severe frontal or retro-orbital headache accompanied by:

Bitemporal hemianopsia from compression of the overlying optic chiasm;

Ophthalmoplegia (ptosis, diplopia) from lateral expansion into the cavernous sinus compressing CN III, IV, and VI;

Acute secondary adrenal insufficiency : Destruction of ACTH-secreting corticotrophs produces sudden cortisol collapse, resulting in refractory hypotension, severe hyponatremia, and hypoglycemia.

Management: Immediate administration of IV stress-dose hydrocortisone (100 mg IV bolus) to avert fatal circulatory shock. Perform urgent brain MRI and obtain emergent neurosurgical consultation for transsphenoidal surgical decompression.